We are live on
!
Find out more
DCM
Defilade Capital Management Portfolio holdings
AUM
$747M
This Fund
S&P 500
This Quarter
Est. Return
+5.84%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$747M
AUM Growth
+$34.8M
(+4.9%)
Cap. Flow
+$1.91M
Cap. Flow
% of AUM
0.26%
Top 10 Holdings %
Top 10 Hldgs %
46.51%
Holding
50
New
19
Increased
9
Reduced
10
Closed
11
Avg Time Held
0.9
quarters
Top 10 Avg Time Held
0.4
quarters
Top 20 Avg Time Held
0.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Veeva Systems
VEEV
|
+$39M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$37.4M |
| 3 |
Insulet
PODD
|
+$29.5M |
| 4 |
Baxter International
BAX
|
+$27.2M |
| 5 |
Abbott
ABT
|
+$26.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Henry Schein
HSIC
|
+$46M |
| 2 |
Becton Dickinson
BDX
|
+$43.9M |
| 3 |
Revolution Medicines
RVMD
|
+$34.1M |
| 4 |
DexCom
DXCM
|
+$33.8M |
| 5 |
Intuitive Surgical
ISRG
|
+$31.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$1.05T
| $46.9M | 6.28% |
39,086
+18,390
| +89% | +$18.8M |
2025 Q4
2 quarters
|
|
2
Pfizer
PFE
$161B
| $42.7M | 5.71% |
1,771,743
+307,614
| +21% | +$8.05M |
2025 Q4
2 quarters
|
|
|
3
Veeva Systems
VEEV
$47.9B
| $42M | 5.62% |
+236,709
| New | +$39M |
2026 Q2
0 quarters
|
|
|
4
BioMarin Pharmaceuticals
BMRN
$10.6B
| $39M | 5.22% |
+682,005
| New | +$37.4M |
2026 Q2
0 quarters
|
|
5
PTC Therapeutics
PTCT
$5.4B
| $35.4M | 4.74% |
433,699
+57,534
| +15% | +$4.15M |
2026 Q1
1 quarter
|
|
|
6
Baxter International
BAX
$12.6B
| $31.1M | 4.17% |
+1,459,380
| New | +$27.2M |
2026 Q2
0 quarters
|
|
7
Insmed
INSM
$22B
| $30M | 4.02% |
281,838
+86,929
| +45% | +$10.5M |
2025 Q4
2 quarters
|
|
8
Zimmer Biomet
ZBH
$17B
| $27.3M | 3.66% |
317,426
-261,735
| -45% | -$22.9M |
2026 Q1
1 quarter
|
|
|
9
Insulet
PODD
$9.38B
| $26.9M | 3.61% |
+176,932
| New | +$29.5M |
2026 Q2
0 quarters
|
|
10
Thermo Fisher Scientific
TMO
$243B
| $26M | 3.49% |
+51,934
| New | +$24.9M |
2026 Q2
0 quarters
|
|
|
11
Abbott
ABT
$172B
| $25.9M | 3.47% |
+285,778
| New | +$26.1M |
2026 Q2
0 quarters
|
|
12
Ascendis Pharma A/S
ASND
$15.1B
| $25.3M | 3.39% |
94,843
+42,948
| +83% | +$10M |
2025 Q4
2 quarters
|
|
13
Solventum
SOLV
$14.9B
| $24.4M | 3.27% |
+316,454
| New | +$23.1M |
2026 Q2
0 quarters
|
|
14
Medtronic
MDT
$113B
| $23.7M | 3.18% |
+303,301
| New | +$24.5M |
2026 Q2
0 quarters
|
|
15
Elanco Animal Health
ELAN
$11.5B
| $21.3M | 2.85% |
864,080
-67,041
| -7% | -$1.55M |
2025 Q4
2 quarters
|
|
16
Agios Pharmaceuticals
AGIO
$1.9B
| $20.3M | 2.72% |
+546,848
| New | +$16.6M |
2026 Q2
0 quarters
|
|
17
Envista
NVST
$3.69B
| $19.1M | 2.56% |
+726,108
| New | +$18.3M |
2026 Q2
0 quarters
|
|
|
18
Revolution Medicines
RVMD
$40.7B
| $15.5M | 2.08% |
82,827
-233,145
| -74% | -$34.1M |
2025 Q4
2 quarters
|
|
19
ICU Medical
ICUI
$4.01B
| $15.5M | 2.07% |
105,700
-148,591
| -58% | -$19.4M |
2025 Q4
2 quarters
|
|
20
Cogent Biosciences
COGT
$5.38B
| $15.2M | 2.04% |
393,441
+40,851
| +12% | +$1.43M |
2025 Q4
2 quarters
|
|
21
Lantheus
LNTH
$6.54B
| $14.7M | 1.97% |
132,662
-116,739
| -47% | -$10.9M |
2026 Q1
1 quarter
|
|
22
Ocular Therapeutix
OCUL
$1.66B
| $14.6M | 1.96% |
1,490,286
+2,641
| +0.2% | +$23.9K |
2025 Q4
2 quarters
|
|
23
Eledon Pharmaceuticals
ELDN
$202M
| $13.9M | 1.86% |
3,525,338
-38,789
| -1% | -$141K |
2025 Q4
2 quarters
|
|
24
Tyra Biosciences
TYRA
$1.37B
| $12M | 1.61% |
+376,870
| New | +$12.5M |
2026 Q2
0 quarters
|
|
25
Olema Pharmaceuticals
OLMA
$684M
| $11.6M | 1.55% |
924,758
-579,778
| -39% | -$7.77M |
2025 Q4
2 quarters
|
|
Similar funds
BG
PCM
JA
ECM
AAM
VCM
IWP
CCME
Defilade Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Defilade Capital Management held 50 positions worth $747M, up 4.9% from $712M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Defilade Capital Management's Q2 2026 filing shows 19 new, 9 increased, 10 reduced and 11 closed positions. Its largest new stake was Veeva Systems: 236,709 shares worth $42M. The largest sale was Henry Schein, an estimated $46M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Defilade Capital Management's largest Q2 2026 buy was Veeva Systems: 236,709 shares worth $42M.
- Defilade Capital Management added most to Eli Lilly in Q2 2026, an estimated $18.8M increase.
- Defilade Capital Management's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $34.1M.
- Defilade Capital Management fully exited Henry Schein in Q2 2026, selling an estimated $46M.
- Defilade Capital Management's ten largest holdings make up 47% of its $747M portfolio in Q2 2026.
- Defilade Capital Management opened 19 new positions and closed 11 in Q2 2026.
- Defilade Capital Management's portfolio value rose 4.9% quarter-over-quarter to $747M.
Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.